Breakout Swing Trading Idea
Last earnings: 2022-08-02
Next earnings: 2022-10-26
Disclaimer: These trading ideas are merely to demonstrate what ChartMill is capable of and shows some typical results of a breakout filter. It is in no way actual financial advise to invest or trade in these stocks. The author has no pre-existing position in any of these stocks.
Triple-digit growth and innovation go hand-in-hand with these companies.
Eli Lilly and Co's COVID-19 drug bebtelovimab is not currently authorized for emergency use in the United States, the Food and Drug Administration said, citing it is not expected to neutralize the dominant BQ.1 and BQ.1.1 subvariants of Omicron. Wednesday's announcement takes away authorization from the last COVID-19 monoclonal antibody treatment, leaving Pfizer Inc's antiviral drug Paxlovid, Merck's Lagevrio and Gilead Sciences' Veklury as treatments for the disease, besides convalescent plasma for some patients. AstraZeneca Plc's monoclonal antibody Evusheld is also authorized for protection against COVID-19 infection in some people.
It would be a continuation of this year's showing.
Sometimes an organization's growth -- and growth story -- is strong enough to overcome marketwide headwinds.
Gilead Sciences (GILD) on Tuesday said the European Commission had approved an expansion for its HIV drug Biktarvy for the use in children
Gilead and Arcus notched another win for their cancer program on Monday. GILD stock briefly hit a four-year high as RCUS stock gapped higher.
Gilead Sciences (GILD) and partner Arcus Biosciences (RCUS) announced Monday the results from their Phase 2 ARC-7 study for lung cancer therapies containing anti-TIGIT and anti-PD-1...
Sales accelerated, again, in the third quarter. Here's what the company and analysts are watching.
The pharmaceutical company's golden goose is about to stop laying golden eggs, but that won't be a permanent problem.